BBP News and Press, Virtus LifeSci Biotech Products From 01/20/20

Despite the biotech industry having pockets of extreme and irrational ebullience, the largest part of the industry is systematically underfunded. It's also the highest-value-add part of the industry from a risk-adjusted basis. In this video, we have a philosophical discussion with the CEO of o...

It's time to talk about a new venture called EQRx. This has made quite a splash in the last few days at the JPMorgan investor conference, and it's been launched by Alexis Borisy (involved with founding and/or helping run CombinatoRx, Foundation, Blueprint, WarpDrive Bio, Editas, Relay, and oth...

Brookfield Asset Management's ( BAM ) global scale and its diversified portfolio offerings stand to benefit immensely from favorable asset management trends such as mandates tilting toward global platforms and capital chasing yields in alternative asset classes at a faster pace than ever befor...

Aprea Therapeutics (NASDAQ: APRE ) opens for trading after raising the size of its IPO to 5.67M shares from 5M and pricing its IPO at $15 , the mid‐point of the $14‐$16 expected range. More news on: Aprea Therapeutics, Monopar Therapeutics, ADC Therapeutics SA, Healthcare st...

The Healthcare sector ranks fourth out of the 11 sectors as detailed in our Q3'19 Sector Ratings for ETFs and Mutual Funds report. Last quarter , the Healthcare sector ranked fifth. It gets our Neutral rating, which is based on an aggregation of ratings of the 322 stocks in the Healthcare...

By Stephen H. Dover, CFA, Executive Vice President, Head of Equities, Krzysztof Musialik, CFA, Research Analyst, Franklin Templeton Emerging Markets Equity, and Steve Kornfeld, CFA, Portfolio Manager, Research Analyst, Franklin Equity Group The biopharma industry has the potential to save...

By Andy Acker, CFA & Luyi Guo, Ph.D., CFA & Rich Carney, CFA Last week, the Trump administration abandoned plans to overhaul drug rebates in Medicare while a federal judge ruled against listing prescription drug prices in TV ads. But U.S. drug reform is far from over, with implica...

By Stephen H. Dover, Executive Vice President, Head of Equities; Aman Gupta, Portfolio Manager, Research Analyst, Franklin Mutual Series; Brian DeChristopher, Research Analyst, Franklin Equity Group; Evan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group; Krzysz...

By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...

By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...